Catastrophic antiphospholipid syndrome: a case series

Area of Science:

• Rheumatology
• Immunology
• Vascular Medicine

Background:

• Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by thrombosis and antiphospholipid antibodies.
• Catastrophic APS (CAPS) is a rare, severe variant involving acute multi-organ failure due to small vessel thrombosis.
• CAPS has a high mortality rate, underscoring the need for understanding its clinical features and management.

Purpose of the Study:

• To evaluate clinical characteristics, thrombotic events, and treatment outcomes in patients with catastrophic APS.
• To identify common manifestations and laboratory findings in a cohort of CAPS patients.
• To assess the effectiveness of various therapeutic interventions in managing CAPS.

Main Methods:

• Retrospective analysis of 11 patients diagnosed with probable or definite catastrophic APS between 2003-2011.
• Review of patient data including thrombotic events, laboratory results, and treatment regimens.
• Histopathologic confirmation of small vessel thrombosis was a key diagnostic criterion.

Main Results:

• A total of 11 patients with catastrophic APS were evaluated, experiencing a combined 28 thrombotic events (18 venous, 10 arterial).
• Common manifestations included deep vein thrombosis, intra-abdominal venous thrombosis, and microangiopathic hemolytic anemia.
• Lupus anticoagulant positivity was universal, with high rates of IgG anticardiolipin and IgG beta2-glycoprotein antibodies; patients were treated with heparin, steroids, and other immunomodulatory agents.

Conclusions:

• Catastrophic APS is a rare but significant condition associated with high morbidity and mortality, particularly in younger individuals.
• Early recognition and aggressive management, including anticoagulation and immunosuppression, are crucial for improving outcomes.
• Further research is needed to optimize treatment strategies for this devastating syndrome.